Literature DB >> 16010417

Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays.

Daisuke Shimizu1, Takashi Ishikawa, Yasushi Ichikawa, Shinji Togo, Yoshihide Hayasizaki, Yasushi Okazaki, Peter V Danenberg, Hiroshi Shimada.   

Abstract

5-Fluorouracil (5-FU) is the most widely used anticancer agent for gastrointestinal cancers. Because many tumors show primary resistance, it is clinically meaningful to predict tumor sensitivity to the drug before treatment. cDNA microarrays containing 21,168 clones were used to identify genes associated with sensitivity to 5-FU. Gene expression profiling of 3 colorectal cancer cell lines (DLD-1, HT-29 and NUGC-3) and the corresponding 5-FU-resistant sublines (DLD-1/FU, HT-29/FU and NUGC-3/5FU/L) showed 81 genes that were differentially expressed. The gene set thus identified successfully predicted the sensitivities of 5 other colorectal cancer cell lines and could also separate 5-FU resistant clinical samples from sensitive ones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010417

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway.

Authors:  Ai-Dong Chen; Hui Li; Yong-Chun Li; Hai Zeng
Journal:  Oncol Lett       Date:  2016-10-26       Impact factor: 2.967

2.  Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.

Authors:  Gregory Lucien Bellot; Wei Han Tan; Ling Lee Tay; Dean Koh; Xueying Wang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-21       Impact factor: 4.553

Review 3.  Genomic and oncoproteomic advances in detection and treatment of colorectal cancer.

Authors:  Seamus M McHugh; Jill O'Donnell; Peter Gillen
Journal:  World J Surg Oncol       Date:  2009-04-01       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.